{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:49:35Z","timestamp":1788569375519,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft DFG","award":["SFB824"],"award-info":[{"award-number":["SFB824"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13550-019-0545-2","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:02:52Z","timestamp":1565690572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1928-6913","authenticated-orcid":false,"given":"Margret","family":"Schottelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ludescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias G.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","volume":"52","author":"E Gourni","year":"2011","unstructured":"Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803\u201310.","journal-title":"J Nucl Med"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.11251","volume":"5","author":"HJ Wester","year":"2015","unstructured":"Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618.","journal-title":"Theranostics"},{"key":"545_CR3","doi-asserted-by":"crossref","first-page":"73387","DOI":"10.18632\/oncotarget.19945","volume":"8","author":"ID Weiss","year":"2017","unstructured":"Weiss ID, Huff LM, Evbuomwan MO, et al. Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64) cu-plerixafor PET. Oncotarget. 2017;8:73387\u2013406.","journal-title":"Oncotarget"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"882","DOI":"10.7150\/thno.12303","volume":"5","author":"Z Wang","year":"2015","unstructured":"Wang Z, Zhang M, Wang L, et al. Prospective study of (68) Ga-NOTA-NFB: radiation dosimetry in healthy volunteers and first application in glioma patients. Theranostics. 2015;5:882\u20139.","journal-title":"Theranostics"},{"key":"545_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","volume":"32","author":"M Kircher","year":"2018","unstructured":"Kircher M, Herhaus P, Schottelius M, et al. CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med. 2018;32:503\u201311.","journal-title":"Ann Nucl Med"},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jcmg.2015.09.008","volume":"8","author":"JT Thackeray","year":"2015","unstructured":"Thackeray JT, Derlin T, Haghikia A, et al. Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction. JACC Cardiovasc Imaging. 2015;8:1417\u201326.","journal-title":"JACC Cardiovasc Imaging"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2967\/jnumed.114.145177","volume":"56","author":"M Schottelius","year":"2015","unstructured":"Schottelius M, Osl T, Poschenrieder A, et al. [177] Lu-pentixather: preclinical and first patient results with a highly promising CXCR4-directed endoradiotherapeutic agent. J Nucl Med. 2015;56:339.","journal-title":"J Nucl Med"},{"key":"545_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.110.085613","volume":"52","author":"RA De Silva","year":"2011","unstructured":"De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011;52:986\u201393.","journal-title":"J Nucl Med"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.2967\/jnumed.110.079418","volume":"51","author":"O Jacobson","year":"2010","unstructured":"Jacobson O, Weiss ID, Kiesewetter DO, Farber JM. Chen X. PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med. 2010;51:1796\u2013804.","journal-title":"J Nucl Med"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1002\/anie.201202090","volume":"51","author":"O Demmer","year":"2012","unstructured":"Demmer O, Frank AO, Hagn F, et al. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew Chem Int Ed Engl. 2012;51:8110\u20133.","journal-title":"Angew Chem Int Ed Engl"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1016\/j.tetlet.2015.10.032","volume":"56","author":"M Schottelius","year":"2015","unstructured":"Schottelius M, Konrad M, Osl T, Poschenrieder A, Wester HJ. An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Lett. 2015;56:6602\u20135.","journal-title":"Tetrahedron Lett"},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1021\/bc0200069","volume":"13","author":"M Schottelius","year":"2002","unstructured":"Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr (3)-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002;13:1021\u201330.","journal-title":"Bioconjug Chem"},{"key":"545_CR13","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/701704","volume":"2012","author":"S Donnou","year":"2012","unstructured":"Donnou S, Galand C, Touitou V, Sautes-Fridman C, Fabry Z, Fisson S. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol. 2012;2012:701704.","journal-title":"Adv Hematol"},{"key":"545_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","volume":"52","author":"E Gourni","year":"2011","unstructured":"Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a Ga-68-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803\u201310.","journal-title":"J Nucl Med"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13550-015-0099-x","volume":"5","author":"M Schottelius","year":"2015","unstructured":"Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [(68) Ga] DOTATATE and [(68) Ga]HA-DOTATATE. EJNMMI Res. 2015;5:22.","journal-title":"EJNMMI Res"},{"key":"545_CR16","doi-asserted-by":"publisher","first-page":"e1016","DOI":"10.1371\/journal.pone.0001016","volume":"2","author":"R Meier","year":"2007","unstructured":"Meier R, Muhlethaler-Mottet A, Flahaut M, et al. The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. PLoS One. 2007;2:e1016.","journal-title":"PLoS One"},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"39701","DOI":"10.1074\/jbc.M509829200","volume":"280","author":"C Akekawatchai","year":"2005","unstructured":"Akekawatchai C, Holland JD, Kochetkova M, Wallace JC, McColl SR. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem. 2005;280:39701\u20138.","journal-title":"J Biol Chem"},{"key":"545_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.bbrc.2004.06.013","volume":"320","author":"H Mochizuki","year":"2004","unstructured":"Mochizuki H, Matsubara A, Teishima J, et al. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun. 2004;320:656\u201363.","journal-title":"Biochem Biophys Res Commun"},{"key":"545_CR19","doi-asserted-by":"publisher","first-page":"17033","DOI":"10.1038\/sigtrans.2017.33","volume":"2","author":"H Guo","year":"2017","unstructured":"Guo H, Ge Y, Li X, et al. Targeting the CXCR4\/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression. Signal Transduct Target Ther. 2017;2:17033.","journal-title":"Signal Transduct Target Ther"},{"key":"545_CR20","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/cmdc.201100320","volume":"6","author":"O Demmer","year":"2011","unstructured":"Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. Chemmedchem. 2011;6:1789\u201391.","journal-title":"Chemmedchem."},{"key":"545_CR21","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1111\/bph.12842","volume":"171","author":"S Thiele","year":"2014","unstructured":"Thiele S, Mungalpara J, Steen A, Rosenkilde MM, Vabeno J. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis. Br J Pharmacol. 2014;171:5313\u201329.","journal-title":"Br J Pharmacol"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/jm040794i","volume":"48","author":"M Schottelius","year":"2005","unstructured":"Schottelius M, Reubi JC, Eltschinger V, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr (ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem. 2005;48:2778\u201389.","journal-title":"J Med Chem"},{"key":"545_CR23","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1128\/JVI.71.9.7097-7100.1997","volume":"71","author":"PD Bieniasz","year":"1997","unstructured":"Bieniasz PD, Fridell RA, Anthony K, Cullen BR. Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1. J Virol. 1997;71:7097\u2013100.","journal-title":"J Virol"},{"key":"545_CR24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-17-1756","volume":"24","author":"HY Fang","year":"2018","unstructured":"Fang HY, Munch NS, Schottelius M, et al. CXCR4 is a potential target for diagnostic PET\/CT imaging in Barrett's dysplasia and esophageal adenocarcinoma. Clin Cancer Res. 2018;24:1048\u201361.","journal-title":"Clin Cancer Res"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-019-0545-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T23:05:55Z","timestamp":1597187155000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-019-0545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s13550-019-0545-2","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"27 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hans-J\u00fcrgen Wester is founder and shareholder of Scintomics GmbH. No other potential conflict of interest relevant to this article was reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"75"}}